CAS 174722-31-7|Rituximab
Introduction：Basic information about CAS 174722-31-7|Rituximab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Rituximab | ||
|---|---|---|---|
| CAS Number | 174722-31-7 | Molecular Weight | / |
| Density | / | Boiling Point | / |
| Molecular Formula | C6416H9874N1688O1987S44 | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | Rituximab |
|---|
Rituximab BiologicalActivity
| Description | Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer[1]. |
|---|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology |
| In Vitro | Rituximab (anti-CD20) inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab (anti-CD20) induces high CDC killing of follicular lymphoma cells[2]. |
| In Vivo | A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3]. |
| References | [1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50. [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54. [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43. |
Chemical & Physical Properties
| Molecular Formula | C6416H9874N1688O1987S44 |
|---|
